Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise
    Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise
    • News

  • DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    • News

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

  • BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    • News

  • Harris Technology eyes profitability as refurbished tech sales surge
    Harris Technology eyes profitability as refurbished tech sales surge
    • News

  • QIC Fund Backs Ark Mines with $4.5m to Accelerate Sandy Mitchell Development
    • News

  • Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    • News

  • FBR’s tech could help reduce housing construction-related cost pressures
    FBR’s tech could help reduce housing construction-related cost pressures
    • News

Director resigns, liquidation fear looms as Phoslock struggles to raise funds after China problems

  • In News
  • September 5, 2023
  • Alinda Gupta
Director resigns, liquidation fear looms as Phoslock struggles to raise funds after China problems

In 2020, water treatment company Phoslock Environmental Technologies (ASX: PET) came under the scanner for accounting irregularities and fraud in its China division. Subsequently, the Company’s financials suffered and it also lost some staff in China. 

Three years later, PET’s China management team has been restructured to reduce costs and focus resources on revenue-generating activity. General Manager Viktor Li left the Company on August 31 after helping stabilise the operations in China following the previous mismanagement issues. Will Li has been appointed to the senior regional commercial role and legal representative for PET’s China sales entity.

Closer to home, Phoslock’s non-executive Director Barry Sechos has thrown in the towel, with his resignation effective from September 6, 2023. Furthermore, the Company will relocate its Corporate Head Office as part of its overall cost reduction program. 

Phoslock informed that it will not be filling Sechos’s position on the Board.

PET has been struggling to gain funding to keep operations going. Its board meetings held on August 10 and August 29, 2023 reviewed various cash flow projections and the statement of financial position. The Board concluded that Phoslock’s ability to keep going as an operational and profitable business, i.e. a going concern, depends on its ability to raise significant additional funds. 

As Phoslock explores funding sources, it is not able to say with certainty whether its efforts will bear fruit. In the absence of adequate funding or alternative transactions in a timely manner, the directors plan to put a resolution to shareholders for voluntary winding-up of the Company. 

In keeping with that, the directors have determined that the going concern basis of accounting is no longer appropriate. Thus, the Company’s interim financial statements were prepared on a non-going concern, i.e. close to liquidation, basis. 

In H1 FY23, the Company reported a revenue of $1 million, down 20% on H1 FY22, and an NPAT loss of $5.2 million. Its net operating cash outflow was $3.5 million. Existing project delays, lack of new projects and fluctuating freight rates put a damper on PET’s objectives.  

On a positive note, in August, PET informed that it had secured a part payment of about $642k in respect of a receivable associated with the Xingyun Lake project in China. The payment was made to PET’s Beijing based subsidiary, Beijing Ecosystime Environmental Science and Technology Co. However, this payment represents just under 10% of the principal owed, which is $7.05 million, with efforts continuing to secure the balance.

Plus, it secured orders for Phoslock applications in Brazil and Finland, with a combined value of $600k, scheduled for September.

Even so, the Company is not very hopeful about its future. The new contract revenues and sales rebuild are not enough to support business operations, remaining well below expectations and requirements. The Company plans on sharing its full FY23 results by September 8, which will determine the way forward.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  •  
  •  
  •  
  •  
  • asx pet
  • Barry Sechos
  • Phoslock
  • water treatment
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.